Livzon Pharmaceutical (000513) Q3 2024 earnings summary

Executive summary

• Net profit attributable to shareholders rose 4.44% year-over-year to RMB 1.67 billion for the first nine months of 2024, despite a 5.94% decline in revenue to RMB 9.08 billion.

• Basic and diluted EPS increased 5.23% year-over-year to RMB 1.81.

• Operating cash flow improved 4.32% year-over-year to RMB 2.31 billion.

Financial highlights

• Q3 revenue was RMB 2.80 billion, down 5.59% year-over-year; Q3 net profit attributable to shareholders was RMB 502 million, up 7.45%.

• Gross margin and operating profit details not specified, but net profit margin improved due to cost controls and non-recurring gains.

• Non-recurring gains contributed RMB 41.93 million for the first nine months.

• Total assets at period end were RMB 24.91 billion; equity attributable to shareholders was RMB 14.16 billion.

Outlook and guidance

• No explicit forward-looking guidance provided, but management commentary suggests continued focus on cost control and product mix optimization.